Western blot shows lysates of human brain (Alzheimer's disease hippocampus) tissue. PVDF Membrane was probed with 2 µg/mL of Mouse Anti-Human/Mouse BACE‑1 Ectodomain Monoclonal Antibody (Catalog # MAB931) followed by ...read more
Mouse myeloma cell line NS0-derived recombinant human BACE-1 Thr22-Tyr460 Accession # P56817
Specificity
Detects human and mouse BACE-1 in direct ELISAs and human BACE-1 in Western blots. In Western blots, no cross-reactivity with recombinant human (rh) BACE-2, recombinant mouse (rm) BACE-2, rhADAM8, rmADAM9, rmADAM10, rhADAM15, or rhTACE is observed.
Source
N/A
Isotype
IgG1
Clonality
Monoclonal
Host
Mouse
Gene
BACE1
Purity
Protein A or G purified from hybridoma culture supernatant
Purity Statement
Protein A or G purified from hybridoma culture supernatant
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.
Beta-site amyloid precursor protein cleaving enzyme 1
Beta-site APP cleaving enzyme 1
beta-site APP-cleaving enzyme 1
beta-site APP-cleaving enzyme
EC 3.4.23
EC 3.4.23.46
FLJ90568
HSPC104
KIAA1149
memapsin-2
Membrane-associated aspartic protease 2
transmembrane aspartic proteinase Asp2
Background
BACE-1 (beta‑site APP cleaving enzyme-1) is an aspartic protease and an integral membrane protein (1, 2). It is the major beta secretase, and together with the gamma secretase, is responsible for generating the amyloid beta peptide (A beta ) from the amyloid precursor protein (APP) (3, 4). Because A beta is a major component of amyloid plaques, BACE-1 has been implicated in the onset and/or progression of Alzheimer's disease. High levels of BACE-1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo, indicating that inhibiting BACE-1 may block not only A beta -dependent but also A beta -independent pathogenic mechanisms (5). In addition to APP, BACE-1 also cleaves APP-like proteins 1 and 2, the cell adhesion protein P-selectin glycoprotein ligand-1 and beta -galactoside alpha 2,6-sialyltransferase, implying that BACE-1 may have additional functions involving the ectodomain shedding of membrane proteins (6‑8).
Vassar, R. et al. (1999) Science 286:735.
Yan, R. et al. (1999) Nature 402:533.
Cai, H. et al. (2001) Nature Neurosci. 4:233.
Roberds, S.L. et al. (2001) Human Mol. Genet. 97:1317.
Rockenstein, E. et al. (2005) J. Biol. Chem. 280:32957.
Li, Q and T.C. Sudhof (2004) J. Biol. Chem. 279:10542.
Lichtenthaler, S.F. et al. (2003) J. Biol. Chem. 278:48713.
Kitazynem, S. et al. (2005) J. Biol. Chem. 280:8589.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Discover related pathways, diseases and genes to BACE-1 Antibody (MAB931). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for BACE-1 Antibody (MAB931)
Discover more about diseases related to BACE-1 Antibody (MAB931).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our BACE-1 Antibody (137612) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.